课题基金 / 基金详情

PROGESTAGEN W/ TRANSDERMAL ANDROGEN VS TA ALONE TO SUPPRESS SPERMATOG

PROGESTAGEN W/ TRANSDERMAL ANDROGEN VS TA ALONE TO SUPPRESS SPERMATOG
孕激素联合经皮雄激素与单独 TA 抑制精子的比较
批准号：
6264888
负责人：
CHRISTINA C. WANG
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264888
关键词：
androgens clinical research clinical trial phase I combination chemotherapy human subject human therapy evaluation male progesterone spermatogenesis inhibitor testosterone

项目摘要

项目成果

CHRISTINA C. WANG的其他基金

相似基金

相关文献

中文摘要
翻译
比较和测试男性激素（睾酮，作为ALZA公司生产的每日皮肤贴片）与女性激素（孕激素：左炔诺孕酮[Norplant II];由人口理事会提供的皮下植入两个胶囊）的组合是否比单独使用睾酮更有效地抑制精子生成。本研究的长期目标是开发一种安全、可逆、实用的男性避孕方法。
英文摘要
To compare and test whether a combination of a male hormone (testosterone, given as a daily skin patch made by ALZA Corporation) together with a female hormone (progestagen: levonorgestrel [Norplant II]; two capsules inserted under the skin provided by the Population Council) is more effective than using testosterone alone in suppressing sperm production. The long term goal of the study is to develop a safe, reversible, practical method of contraception for man.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Community Outreach and Education Core (Core B)
Community Outreach and Education Core (Core B)
Community Outreach and Education Core (Core B)
GENERAL CLINICAL RESEARCH CENTER
海外基金